Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors

Document Details

Document Type
Pub Defense Publication
Publication Date
Dec 01, 2017
Source ID
10.1074/jbc.m117.799593

Entities

People

  • Alla Volgina
  • Douglas B. Cines
  • Elena N. Atochina-vasserman
  • Fedor G. Zabozlaev
  • Kelci R. Holman
  • Konstantin V. Dergilev
  • Kseniya Obraztsova
  • Mimi Teter
  • Sergei V. Zaitsev
  • Shane P. Lewis
  • Vera P. Krymskaya
  • Victoria Stepanova
  • Yelena V. Parfyonova
  • Zoya I. Tsokolaeva

Organizations

  • Congressionally Directed Medical Research Programs
  • National Heart, Lung, and Blood Institute
  • Perelman School of Medicine at the University of Pennsylvania
  • Russian Science Foundation